摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-phenyl-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine | 132206-99-6

中文名称
——
中文别名
——
英文名称
N-phenyl-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine
英文别名
N-Phenyl-2-cyclopentyl-1H-imidazo(4,5-C)quinolin-4-amine;2-cyclopentyl-N-phenyl-3H-imidazo[4,5-c]quinolin-4-amine
N-phenyl-2-cyclopentyl-1H-imidazo[4,5-c]quinolin-4-amine化学式
CAS
132206-99-6
化学式
C21H20N4
mdl
——
分子量
328.417
InChiKey
VUYDJBYOJKYWBY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    155-157 °C(Solv: methanol (67-56-1); water (7732-18-5))
  • 沸点:
    614.5±40.0 °C(Predicted)
  • 密度:
    1.303±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    53.6
  • 氢给体数:
    2
  • 氢受体数:
    3

SDS

SDS:c24966fc188ce1fafd3412762ab05963
查看

反应信息

  • 作为产物:
    参考文献:
    名称:
    新的1H-咪唑并[4,5-c]喹啉-4-胺衍生物作为A3腺苷受体的变构增强剂的构效关系。
    摘要:
    1H-咪唑并[4,5-c]喹啉-4-胺衍生物已被合成为人类A3腺苷受体(AR)的变构调节剂。在4-氨基和2位上进行结构修饰。在结合和功能测定中都测试了该化合物,并且通过几种不同的标准,发现许多化合物是A3AR激动剂作用的变构增强剂。首先,对于许多衍生物,观察到了激动剂C1-IB-MECA的最大功效的增强。同样,许多这些化合物降低了激动剂[125I] I-AB-MECA从A3AR的解离速率。最显着的是,发现化合物43(LUF6000)在功能测定中可将激动剂功效提高45%,并在不影响激动剂效价的情况下类似地降低解离速率。A3AR的变构增强的结构要求不同于抑制平衡结合的要求。因此,我们制备了人A3AR的变构增强剂,其与在正构位点抑制平衡结合相比具有改善的变构作用。
    DOI:
    10.1021/jm060086s
点击查看最新优质反应信息

文献信息

  • A3 Adenosine receptor allosteric modulators
    申请人:Goblyos Aniko
    公开号:US20090054476A1
    公开(公告)日:2009-02-26
    The present invention relates to allosteric modulation of A 3 adenosine receptor (A 3 AR) and provides for the use of an A 3 adenosine receptor modulator (A 3 RM), for the preparation of pharmaceutical compositions for modulating the A 3 AR in a subject, as well as pharmaceutical compositions comprising the same and therapeutic methods comprising administering to a subject an amount of an A 3 RM, the amount being effective to modulate A 3 AR activity. The A 3 RM according to the invention are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. The invention also provides some of such novel 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.
    本发明涉及A3腺苷受体(A3AR)的变构调节,并提供了使用A3腺苷受体调节剂(A3RM)制备调节受体的药物组合物的方法,以及包含相同的药物组合物和治疗方法,包括向受体中注射有效量的A3RM以调节A3AR活性。本发明中的A3RM是1H-咪唑-[4,5-c]喹啉-4-胺衍生物。本发明还提供了一些这种新型1H-咪唑-[4,5-c]喹啉-4-胺衍生物。
  • A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS
    申请人:GÖBLYÖS Anikó
    公开号:US20130197025A1
    公开(公告)日:2013-08-01
    The claimed subject matter relates to allosteric modulation of A 3 adenosine receptor (A 3 AR) and provides for the use of an A 3 adenosine receptor modulator (A 3 RM), for the preparation of pharmaceutical compositions for modulating the A 3 AR in a subject, as well as pharmaceutical compositions including the same and therapeutic methods including administering to a subject an amount of an A 3 RM, the amount being effective to modulate A 3 AR activity. The A 3 RM according to claimed subject matter are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. Also provided are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.
    所述主题涉及A3腺苷受体(A3AR)的变构调节,并提供使用A3腺苷受体调节剂(A3RM)制备调节受体的制药组合物,以及包括相同的制药组合物和治疗方法,包括向受体内注射有效量的A3RM,该量足以调节A3AR活性。根据所述主题,A3RM是1H-Imidazo-[4,5-c]quinolin-4-amine衍生物。还提供了1H-Imidazo-[4,5-c]quinolin-4-amine衍生物。
  • 1H-Imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists
    作者:Philip J. M. Van Galen、Peter Nissen、Ineke Van Wijngaarden、Adriaan P. Ijzerman、Willem Soudijn
    DOI:10.1021/jm00107a046
    日期:1991.3
    On the basis of a model we recently developed for the antagonist binding site of the adenosine A1 receptor (J. Med. Chem. 1990, 33, 1708-1713), it was predicted that H-1-imidazo[4,5-c]quinolin-4-amines would be antagonists of the A1 receptor. Furthermore, it was expected that certain hydrophobic substitutions at the 2- and 4-positions would enhance affinity. Here, we report on the synthesis and the adenosine A1 and A2 recpetor affinity of substituted H-1-imidazo[4,5-c]quinolin-4-amines. Some of these compounds have nanomolar affinity for the A1 receptor. The structure-activity relationships (SAR) of these compounds are discussed in relation to SAR for other adenosine receptor ligands. The H-1-imidazo[4,5-c]quinolin-4-amines constitute a novel class of non-xanthine adenosine antagonists.
  • WO2007/89507
    申请人:——
    公开号:——
    公开(公告)日:——
  • VAN, GALEN PHILIP J. M..;NISSEN, PETER;VAN, WIJNGAARDEN INEKE;JZERMAN, AD+, J. MED. CHEM., 34,(1991) N, C. 1202-1206
    作者:VAN, GALEN PHILIP J. M..、NISSEN, PETER、VAN, WIJNGAARDEN INEKE、JZERMAN, AD+
    DOI:——
    日期:——
查看更多